← All trials
NCT03674073
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2018
- Primary completion
- Oct 15, 2020
- Completion date
- Dec 15, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- People's Liberation Army of ChinaLead sponsor
- People's Liberation Army of ChinaReponsible party - principal investigator
- People's Liberation Army of ChinaOverall official - principal investigator
- Likang Life SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.